Abstract |
Hereditary angioedema type I (HAE-C1-INH) is an inherited disorder characterized by repeated severe angioedema attacks mostly triggered by traumas, emotional stress, increased estrogen levels or surgical procedures, in particular, odontostomatological interventions. Icatibant, a bradykinin B2 receptor antagonist, has been approved for treatment of HAE attacks. In this paper we describe the off label administration of icatibant as short-term prophylaxis of dental extraction in a patient with HAE with the aim of preventing perioperative angioedema attacks. The drug showed an effective and safe profile. Thus, a short-term prophylaxis of angioedema attacks in patients with HAE may be arranged on a multidisciplinary basis, according to the clinical history of each single patients.
|
Authors | C Angeletti, P M Angeletti, F Mastrobuono, L Pilotti, A Ciccozzi, C Guetti |
Journal | International journal of immunopathology and pharmacology
(Int J Immunopathol Pharmacol)
2014 Oct-Dec
Vol. 27
Issue 4
Pg. 653-9
ISSN: 0394-6320 [Print] England |
PMID | 25572747
(Publication Type: Case Reports, Letter)
|
Chemical References |
- Bradykinin B2 Receptor Antagonists
- icatibant
- Bradykinin
|
Topics |
- Angioedemas, Hereditary
(prevention & control)
- Bradykinin
(analogs & derivatives, therapeutic use)
- Bradykinin B2 Receptor Antagonists
(therapeutic use)
- Female
- Humans
- Middle Aged
- Off-Label Use
|